$BSX

LUDWIG EDWARD J purchased $227K of BSX

LUDWIG EDWARD J purchased 5,000 shares of BOSTON SCIENTIFIC CORP (BSX) at $45.48 ($0.23M total) on 2026-07-31.

Original reporting
SEC EDGAR · LUDWIG EDWARD J
Published Aug 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BSX
Neutral
medium confidence
Mentioned
$BSX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BSXNeutralLow
01

Why it matters

A director’s open-market purchase is new information, but it does not include any operational, financial, or regulatory development for BSX.

02

Market read

Traders may note the insider buy as a mild sentiment input, but it is unlikely to override fundamentals without accompanying company news.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not reveal the insider’s rationale or whether the purchase is opportunistic versus conviction.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-03, transaction dated 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for Boston Scientific (BSX).

Company-level read

Ticker impact

$BSXNeutralMedium confidence
Context

Boston Scientific disclosed an insider open-market purchase by director Ludwig Edward J for 5,000 shares at $45.4799 on 2026-07-31.

Expected impact

Likely limited near-term price impact; any effect is more sentiment than fundamentals.

Evidence & confidence

Form 4 provides a new transaction date and size, yet insider purchases are typically lower-signal than company-issued financial or strategic disclosures.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory or product signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (compensation-related, diversification, or planned trading) and may not reflect a change in business outlook.

Key entities

  • Boston Scientific Corp

    Subject of the Form 4 insider transaction disclosure.

  • Ludwig Edward J

    Director who purchased 5,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BSXMedAI 8/10

Boston Scientific stock drops on duidance cut (BSX:NYSE)

Boston Scientific (BSX) shares declined in premarket trading Wednesday despite Q3 2026 earnings beating expectations. The company reduced its full-year outlook, attributing the change to a recent cybersecurity incident. According to the company, the incident impacted its financial performance. BSX reported Q3 2026 financials but did not disclose specific figures in the provided text.

$BSXHighAI 8/10

Why is Boston Scientific stock sliding today?

Boston Scientific (BSX) shares fell 3.6% to $43.42 in pre-market trading after reporting Q3 2026 earnings. Adjusted EPS of $0.73 missed estimates by $0.02, while revenue of $5.14B exceeded expectations. The company cut Q4 and full-year 2026 EPS guidance due to a cyberattack and other challenges, citing a 1%-3% expected decline in Q4 sales.